Cancer Epidemiology
Volume 34, Issue 3 , Pages 274-278 , June 2010

Acute myeloid leukemia incidence following radiation therapy for localized or locally advanced prostate adenocarcinoma

  • Rohit P. Ojha

      Affiliations

    • Department of Epidemiology, University of North Texas Health Science Center, Fort Worth, TX, USA
    • Corresponding Author InformationCorresponding author at: 3500 Camp Bowie Blvd. CBH Suite 355, Fort Worth, TX 76107, USA. Tel.: +1 817 735 5029.
    • ,
  • Lori A. Fischbach

      Affiliations

    • Department of Epidemiology, University of North Texas Health Science Center, Fort Worth, TX, USA
    • ,
  • Yi Zhou

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, USA
    • ,
  • Martha J. Felini

      Affiliations

    • Department of Epidemiology, University of North Texas Health Science Center, Fort Worth, TX, USA
    • ,
  • Karan P. Singh

      Affiliations

    • Department of Biostatistics, University of North Texas Health Science Center, Fort Worth, TX, USA
    • ,
  • Raymond Thertulien

      Affiliations

    • Cancer Centers of North Carolina, US Oncology, Asheville, NC, USA

,Accepted 4 April 2010.

References 

  1. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35(August (4)):418–429
  2. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(October (10)):1389–1398
  3. Roychoudhuri R, Evans H, Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer. 2004;91(August (5)):868–872
  4. Boice JD, Engholm G, Kleinerman RA, Blettner M, Stovall M, Lisco H, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res. 1988;116(October (1)):3–55
  5. Gershkevitsh E, Rosenberg I, Dearnaley DP, Trott KR. Bone marrow doses and leukaemia risk in radiotherapy of prostate cancer. Radiother Oncol. 1999;53(December (3)):189–197
  6. Müller AC, Ganswindt U, Bamberg M, Belka C. Risk of second malignancies after prostate irradiation?. Strahlenther Onkol. 2007;183(November (11)):605–609
  7. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol. 1999;149(June (11)):981–983
  8. Austin PC, Mamdani MM, Juurlink DN, Hux JE. Testing multiple statistical hypotheses resulted in spurious associations: a study of astrological signs and health. J Clin Epidemiol. 2006;59(September (9)):964–969
  9. National Cancer Institute. Surveillance epidemiology and end results. Available at: http://seer.cancer.gov/about/ [accessed January 2010].
  10. National Cancer Institute. Surveillance epidemiology and end results. SEER coding and staging manuals. Available at: http://seer.cancer.gov/tools/codingmanuals/index.html [accessed June 2009].
  11. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed.. Philadelphia, PA: Lippincott, Williams, & Wilkins; 2008;
  12. World Health Organization. International classification of diseases for oncology, 3rd ed. (ICD-O-3). Available at: http://www.who.int/classifications/icd/adaptations/oncology/en/ [accessed June 2009].
  13. Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol. 1997;10(June (6)):612–629
  14. Varghese SL, Grossfeld GD. The prostatic gland: malignancies other than adenocarcinomas. Radiol Clin North Am. 2000;38(January (1)):179–202
  15. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R. Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int. 2008;102(November (10)):1369–1374
  16. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol. 2004;17(March (3)):316–327
  17. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French–American–British Cooperative Group. Ann Intern Med. 1985;103(October (4)):620–625
  18. Pearl J . Causality: models, reasoning, and inference. 2nd ed.. New York, NY: Cambridge University Press; 2009;
  19. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(January (1)):37–48
  20. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. BMC Med Res Methodol. 2008;8(October):70
  21. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(May (14)):1908–1915
  22. Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008;19(May (4)):379–390
  23. Lichtman MA. Cigarette smoking, cytogenetic abnormalities, and acute myelogenous leukemia. Leukemia. 2007;21(June (6)):1137–1140
  24. Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. Int J Cancer. 2008;122(March (6)):1418–1421
  25. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(June (6)):2106–2131
  26. Mordkin RM, Hayes WS, Kuettel MR, Lynch JH. Management of locally advanced prostate cancer. Oncology (Williston Park). 1996;10(September (9)):p. 1289, 1299–300 [discussion 1300–6]
  27. Delongchamps NB, Wang CY, Chandan V, Jones RF, Threatte G, Jumbelic M, et al. Pathological characteristics of prostate cancer in elderly men. J Urol. 2009;182(September (3)):927–930
  28. Houterman S, Janssen-Heijnen ML, Verheij CD, Kil PJ, van den Berg HA, Coebergh JW. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis. 2006;9(2):179–184
  29. Shavers VL, Brown ML, Potosky AL, Klabunde CN, Davis WW, Moul JW, et al. Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med. 2004;19(February (2)):146–155
  30. Marr PL, Elkin EP, Arredondo SA, Broering JM, DuChane J, Carroll PR. Comorbidity and primary treatment for localized prostate cancer: data from CaPSURE. J Urol. 2006;175(April (4)):1326–1331
  31. Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009;12(3):259–263
  32. AJCC cancer staging manual. 6th ed.. New York, NY: American Joint Committee on Cancer; Springer-Verlag; 2002;
  33. Austin PC. Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes. J Clin Epidemiol. 2010;63(January (1)):46–55
  34. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88(January (2)):398–406
  35. Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107(September (5)):991–998
  36. Neugut AI, Ahsan H, Robinson E, Ennis RD. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer. 1997;79(April (8)):1600–1604
  37. McMaster ML, Feuer EJ, Tucker MA . New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006;[NIH Publication No. 05-5302]
  38. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(September (5)):615–625
  39. Liauw SL, Sylvester JE, Morris CG, Blasko JC, Grimm PD. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys. 2006;66(November (3)):669–673
  40. Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer—a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(September (1)):58–68
  41. Voulgaris S, Nobes JP, Laing RW, Langley SE. State-of-the-art: prostate LDR brachytherapy. Prostate Cancer Prostatic Dis. 2008;11(3):237–240
  42. Nguyen PL, Trofimov A, Zietman AL. Proton-beam vs. intensity-modulated radiation therapy. Which is best for treating prostate cancer?. Oncology (Williston Park). 2008;22(June (7)):p. 748–54 [discussion 754, 757]
  43. Roberts WB, Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol. 2009;18(September (3)):268–274
  44. Chalasani V, Iansavichene AE, Lock M, Izawa JI. Salvage radiotherapy following radical prostatectomy. Int J Urol. 2009;16(January (1)):31–36
  45. Cox JM, Busby JE. Salvage therapy for prostate cancer recurrence after radiation therapy. Curr Urol Rep. 2009;10(May (3)):199–205
  46. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(July (4)):488–495
  47. Hafeman DM, Schwartz S. Opening the Black Box: a motivation for the assessment of mediation. Int J Epidemiol. 2009;38(June (3)):838–845
  48. Puskin JS. Perspective on the use of LNT for radiation protection and risk assessment by the U.S. Environmental Protection Agency. Dose Response. 2009;7(4):284–291
  49. Dreicer R. Current status of cytotoxic chemotherapy in patients with metastatic prostate cancer. Urol Oncol. 2008;26(July–August (4)):426–429
  50. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008;26(March (9)):1532–1536

PII: S1877-7821(10)00065-2

doi: 10.1016/j.canep.2010.04.003

Cancer Epidemiology
Volume 34, Issue 3 , Pages 274-278 , June 2010

Article Tools

* Image Usage & Resolution